TREATMENT OF ANEMIA IN GYNECOLOGICAL PATIENTS


Cite item

Full Text

Abstract

The new drug Cosmofer that is an iron(III)-hydroxide low-molecular-weight dextran complex and a chemically similar analogue of the physiological complex of ferritin with iron(III)-hydroxide has been used to treat 30 patients with iron-deficiency anemia caused by menorrhagias in the presence of endometrial hyperplasia and uterine myoma. Before treatment, hemoglobin levels in the patients ranged from 65 to 80 g/l (mean 70.1±3.5 g/l). The drug was intravenously injected dropwise in a dose of 100 mg (2 ml) every other day (thrice weekly). The course of therapy was 3 to 5 infusions; the total dose of iron administered was 300 to 500 mg. After Cosmofer treatment, the mean level of hemoglobin was as high as 98.1+2.8 g/l, which is indicative of the high clinical efficacy of the drug in the treatment of iron-deficiency and posthemorrhagic anemias in gynecological patients.

References

  1. Дедов И.И., Андреева Е.Н. Гиперплазия эндометрия: патогенез, диагностика, клиника, лечение: Метод. пособие для врачей. - М., 2001.
  2. Идельсон Л.И. Гипохромные анемии. - М.: «Медицина», 1981.
  3. Козловская Л.В., Рамеев В.В., Чеботарева Н.М. и др. Анемия хронических заболеваний // Врач. - 2006. - № 4. - С. 17-20.
  4. Манухин И.Б., Крапошина Т.П., Левченко Р.Г. Опыт лечения анемии в гинекологической практике // АГ-инфо по акуш. и гин. - 2001. - № 3. - С. 46-47.
  5. Милованова Л.Ю., Николаев А.Ю., Козлова Т.А. и др. Прогностическое значение ранней коррекции анемии у больных хронической почечной недостаточностью // Нефрол. и диализ. - 2004. - № 1. - С. 54-57.
  6. Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy- related anemia: a multi-centr., open-label, randomized trial// J. Clin. Oncol. - 2004. - Vol. 22. - P. 1301- 1307.
  7. Auerbach M. Intravenous iron // N. Engl. J. Med. - 2007. - Vol. 357. - P. 93-94.
  8. Balan V., Schwartz D., Wu G.Y. et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin // Am. J. Gastroenterol. - 2005. - Vol. 100. - P. 299- 307.
  9. Bellet R.E., Ghazal H, Flam M. et al. Anthonyf of the iron Sucrose Study Group. A phase III randomized, controlled study comparing iron sucrose intravenously (III) to no iron treatment of anaemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy// J.Clin. Oncol.; ASCO Annual Meeting Proceedings. Pt 1. - 2007. - Vol. 25. - abstr. 9109.
  10. Hamstra R.D., Block M.H., Schocket A.L. Intravenous iron dextran in clinical medicine// J.A.M.A. - 1980. - Vol. 243. - P. 1726-1731.
  11. Littlewood T.J., Alikhan R. The use of intravenous iron on patients with cancer-related anaemia// Br. J. Haematol. - 2008. - Vol.141, N 6. - P. 751-756.
  12. Rossert J., Munfer P. et al. Effect of early correction of anemia on the progression of chronic kidney disease// Am. J. Kidney Dis. - 2006. - Vol. 12. - P. 123- 130.
  13. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options // Am. J. Hematol. - 2004. - Vol. 76. - P. 74-78.
  14. Weiss G., Goodnough L.T. Anemia of chronic disease// N. Engl. J. Med. - 2005. - Vol. 352. - P. 1011- 1023.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies